

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



撥康視云™
Cloudbreak Pharma

CLOUDBREAK PHARMA INC.

撥康視雲製藥有限公司*

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2592)

UPDATE ANNOUNCEMENT

Reference is made to the announcement of Cloudbreak Pharma Inc. (the “**Company**”) dated 30 March 2026 in relation to the temporary deviation from the Use of Proceeds and a notifiable transaction (the “**Announcement**”). Unless otherwise defined herein, terms used in this announcement shall have the same meanings as those defined in the Announcement.

UPDATE ON THE FUND REDEMPTION

As disclosed in the Announcement, the Board has resolved to redeem the Fund immediately to mitigate the impacts of the non-compliance and to ensure compliance with the Use of Proceeds. As at the date of this announcement, the Fund has been redeemed in full, and the Company has received redemption proceeds of approximately HK\$48.0 million from the Fund and recorded a gain of approximately HK\$0.88 million upon redemption, representing an annualised return rate of approximately 2.53%.

FURTHER INFORMATION OF THE FUND

As disclosed in the Announcement, the Fund is an exempted company incorporated with limited liability, registered as a segregated portfolio company under the laws of the Cayman Islands and supervised by the Cayman Islands Monetary Authority. The Fund is a registered investment fund with a wide investor base. As at the date of this announcement, the Fund has assets under management (AUM) exceeding US\$100 million and has over 10 investors including large multinational corporations, family offices, charitable foundations and endowment funds. None of the investors of the Fund holds more than 10% interest in the Fund. Ms Saadeddine Hanane, the director and ultimate beneficial owner of the Fund’s general partner, has the right to exercise the Fund’s voting rights and controls the Fund. Therefore, Ms Saadeddine Hanane is deemed as the ultimate beneficial owner of the Fund.

As at the date of this announcement, to the best of the knowledge, information and belief of the Directors and having made all reasonable enquiries, each of the Fund, the parties mentioned above and their respective ultimate beneficial owners is an independent third party of the Company and its connected persons.

By order of the Board
Cloudbreak Pharma Inc.

Dr. NI, Jinsong

Chairman, Executive Director and Chief Executive Officer

Hong Kong, 22 April 2026

As at the date of this announcement, the Board comprises: (i) Dr. Ni Jinsong, Mr. Dinh Son Van, Dr. Yang Rong as executive Directors; (ii) Dr. Li Jun Zhi, Mr. Cao Xu and Mr. Xia Zhidong as non-executive Directors; and (iii) Ms. Nie Sijiang, Mr. Ma Yiu Ho Peter, Mr. Lee Alex Jao Jang as independent non-executive Directors.

* *For identification purposes only*